Connect with us


North Charleston Auto Repair Shop Freedom Transmissions Plus Services All Foreign And Domestic Vehicles



Freedom Transmissions Plus is a full service auto repair shop located in North Charleston that works on all makes and models of foreign and domestic vehicles. We service cars, trucks, coupes, and other types of vehicles and can help you with all of your vehicle repair and maintenance needs.

We provide the following services to vehicle owners in the Greater Charleston Area: brake repair and replacement, transmission rebuilds and replacement, engine tune ups and repairs, as well as manufacturer suggested service intervals. We help keep your car running at optimal efficiency so you can get more life out of your vehicle.

If you hear any weird sounds or noises, don’t assume that all is well with your vehicle. Often times, your vehicle is trying to tell you something. Fortunately, many newer vehicles will have dashboard lights to alert us when something is wrong, but if you drive an older model vehicle and you hear something in your engine compartment, when you brake, or if your steering wheel shakes, it may be time to have work performed to your car or truck.

Don’t put off service intervals and routine maintenance that your car needs – it will cost you more money in the long run by letting existing damage or problems worsen. Come to Freedom Transmissions Plus located at 3363 North American Street North Charleston, South Carolina 29418 for the best auto mechanic in Greater Charleston SC.  Schedule your appointment with us today by calling 843-225-2920.

Continue Reading


Order Wholesale PPE Supplies and COVID-19 Diagnostic Testing Kits Online from GWHP Corp




Global WholeHealth Partners is proud to be a leader in the PPE supplies industry when it comes to sourcing PPE supplies and COVID-19 diagnostic testing kits. While we are excited to see the progress made with the Pfizer and Moderna vaccines, it is imperative that we continue to use PPE supplies and know our status when it comes to whether or not we are infected with the coronavirus.

COVID-19 is still not entirely under control, and while travel is beginning to ramp up and many states and local communities are relaxing their social distancing guidelines and mask requirements, we can still all do our part to be careful. Frequent hand washing and the use of PPE supplies can help ensure we continue to slow the spread of COVID-19.

We stand committed to sourcing and supplying in demand COVID-19 diagnostic testing kits and personal protective equipment. We offer these products in bulk quantities and interested parties can visit our medical supply page to view current inventory levels.

By social distancing where we can, staying quarantined when we are sick, and using PPE supplies when leaving the house, we can help get COVID-19 under control. Masks wearing is still required or recommended in most public indoor places such as shopping malls, grocery stores and restaurants and often times negative COVID-19 tests are required for travel.

Get in touch with Global WholeHealth Partners today to place your order for wholesale PPE supplies or wholesale COVID-19 testing kits, or both, depending on your needs. We continue to source and supply these in demand products for our customers across the country. Call 877-568-4947 to start your order now.

About Global WholeHealth Partners OTC (GWHP)
GWHP provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines that detect between 1 – 1 ½ hours and Rapid Diagnostic Testing (RDT) Serum Plasma that detect between 15 -20 minutes, which predict diseases ahead of its industry competitors. Our focus is encompassing, improving, and preserving the quality of life by providing fast, adequate and accurate test results to prompt early treatment and cut cost of accumulated diseases all over the world. By so doing, GWHP has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. MISSION GWHP is committed to building long term shareholder value through the vertical integration of proven, well established business that effectively and efficiently control disease outbreak and significantly reducing health care costs. VISION Our vision is to lead the industry in infectious disease diagnostics and provide molecular solutions that lessen the time to diagnose medical results, empower healthcare professionals to make better diagnostic decisions, and lower healthcare costs.

Continue Reading


Classworx, Inc. Files First Quarter Ending March 31, 2021 Audit Review in FORM S1 Filing with S.E.C.




Classworx Inc., a Delaware Corporation (OTC PINK:CHNO), owner of, a community for people hosting Zoom events that can list their Zoom classes, performances and events inside their Classworx™ profile on, has completed its first quarter ending March 31, 2021 audit review and has filed a current FORM S1 with S.E.C.

Classworx, Inc. has completed the company audit with the Auditing Firm BF Borgers CPA PC Certified, Public Accountants. Classworx, Inc. completed two years of audited financials for 2019 and 2020 along the first quarter ending March 31, 2021 audit review. With the financials being audited, the company is now fully reporting.

The Law Offices of Thomas C. Cook prepared the FORM S1 for filing and it has been submitted through original filing through EDGAR on June 3, 2021 and the additional filing on June 17, 2021 that includes the first quarter of 2021.

Raymond Firth stated, “We are continuing to take the steps necessary to build out with tools that will compliment anyone using Zoom that is looking to attract more attendees, while becoming fully reporting to qualify to uplist from the OTC Pinksheets.”

The S1 is priced at $5.00 per share which is currently higher than the current stock price. The amount of shares in the offering is a total of five million shares which would amount to $25,000,000.00 (twenty five million dollars) if the raise is 100% subscribed. The proceeds would be used for development, advertising, public relations and marketing of the website and the build out of the Classworx™ App.

Form S-1 Classworx Inc.

About The Law Offices of Thomas C. Cook
The Law Offices of Thomas C. Cook was formed in Las Vegas, Nevada, in 1997, with a principal focus of representing public companies before the United States Securities and Exchange Commission, FINRA, OTC Markets, LLC, and the various state securities authorities. Thomas C. Cook, Esq., the firm’s principal attorney, has over two decades of experience in corporate and securities law, including but not limited to corporate formation and governance, securities registrations and compliance, mergers and acquisitions, and the issuance of securities-related opinions. Mr. Cook received his bachelor of arts from Occidental College in 1990 and his Juris Doctor from Whittier Law School in 1993.

About BF Borgers CPA, PC​​​​​
At BF Borgers CPA, PC, we have built our practice by providing exceptional service to our clients through our commitment to our firm culture and values based on the three underlying principals Professionalism, Responsiveness, Quality.

About Classworx, Inc. (formerly known as Chill N Out Cryotherapy, Inc.)
Chill N Out Cryotherapy, Inc. now known as Classworx, Inc. (OTC PINK:CHNO), a Delaware Corporation, owns and operates Classworx, Inc. currently trades on the OTC Pinks under the stock symbol CHNO. Classworx™ provides an internet-based, global network-directory of people offering Virtual classes or events utilizing video conferencing to remotely deliver individual or group instruction in a broad range of disciplines (‘virtual classes’). The Company is based in the Atlanta, Georgia, area spans a global outreach through the worldwide web.

Safe Harbor:
This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the ‘Exchange Act’), including statements regarding potential sales, the success of the company’s business, as well as statements that include the word believe or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of Findit Inc. to differ materially from those implied or expressed by such forward-looking statements. This press release speaks as of the date first set forth above, and Findit Inc. assumes no responsibility to update the information included herein for events occurring after the date hereof. Actual results could differ materially from those anticipated due to factors such as the lack of capital, timely development of products, inability to deliver products when ordered, inability of potential customers to pay for ordered products, and political and economic risks inherent in international trade.

Raymond Firth

SOURCE: Classworx

Continue Reading


Global WholeHealth Partners Corp (GWHP-OTC) Acquires Rights to Distribute & Sell a 2nd COVID-19 Vaccine – The Pfizer-BioNTech




The Pfizer-BioNTech Was Found to be More Than 95% Effective Against Severe Disease or Death From Variants

Company Now Has the Rights to Distribute & Sell Both the Pfizer-BioNTech and J&J COVID-19 Vaccines; Respectively, the Most Effective and the Most Convenient Vaccines

Global WholeHealth Partners Corp. (OTC: GWHP), a company that offers one of the largest lines of COVID-19 tests including SARS-CoV-2 viruses and that states that its Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses, and that recently announced that they had acquired the rights to be able to distribute and sell Johnson & Johnson’s COVID-19 vaccine, today announced that they have now, also, acquired the rights to sell and distribute Pfizer’s vaccine.

As with the Johnson & Johnson, the Pfizer-BioNTech 8K was filed on June 10, 2021, for the J&J rights and Pfizer-BioNTech, the Company has also filed an 8K on June 16, 2021, stating that “Effective June 4, 2021, Global WholeHealth Partners Corporation (the ‘Company’) was granted the rights from Nunzia Pharmaceutical Inc. (‘Nunzia’) to distribute and sell the Pfizer-BioNTech COVID-19 Vaccine. The Company will serve as a broker for Nunzia and follow the same sales order processing as used by Nunzia in connection with the distribution and sale of the Vaccine.”[1]

On December 11, 2020, Pfizer became the first COVID-19 vaccine to gain an FDA EUA, after the company reported positive clinical trial data, which included news that the vaccine was up to 95% effective at preventing symptomatic disease. According to Yale Medicine[2], they said that: “(Pfizer’s vaccine has a) 95% efficacy in preventing COVID-19 in those without prior infection. The researchers report that the vaccine was equally effective across a variety of different types of people and variables, including age, gender, race, ethnicity, and body mass index (BMI)—or presence of other medical conditions. In clinical trials, the vaccine was 100% effective at preventing severe disease… and in early May, the Pfizer-BioNTech vaccine was found to be more than 95% effective against severe disease or death from the variants first detected in the United Kingdom (B.1.1.7, or the Alpha variant) and South Africa (B.1.351, or the Beta variant) in two studies based on real-world use of the vaccine. While the efficacy against infection varied between the two studies, both also showed the vaccine provides strong protection.”

The Company already offers one of the largest lines of COVID-19 tests, including the strains identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) strain contains multiple mutations, most reflected in the S gene, which encodes the spike protein.

Mr. Charles Strongo, the CEO and Chairman of WholeHealth Products Inc., said: “Global will now have both J&J’s extremely convenient 1-shot vaccine, and we now have the rights to the Pfizer-BioNTech vaccine, which is generally considered the highest efficacy.”

About Global WholeHealth Partners Corp

GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. The Company has the capacity to deliver hundreds of thousands of tests, and can ramp up to 1 million tests per day and the Company presently has 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the FDA, many of which are Approved for OTC use, and 15 POC products approved by the CLIA WAIVED FDA.

For more information please go

Sales: 714-392-3423,

Media: Charles Strongo 714-392-9752

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Continue Reading